The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.

Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.

Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.

A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.

Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.